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Toll-like receptors (TLRs) are pattern recognition receptors which mediate an inflammatory 
response upon the detection of specific molecular patterns found on foreign organisms and on 
endogenous damage-related molecules. These receptors play a major role in the activation of 
microglia, the innate immune cells of the CNS, and are also expressed in peripheral tissues, 
including blood mononuclear cells and the gut. It is well established that immune activation, 
in both the brain and periphery, is a feature of Parkinson’s disease as well as other α-
synucleinopathies. Aggregated forms of α-synuclein can act as ligands for TLRs (particularly 
TLR2 and TLR4), and hence these receptors may play a critical role in mediating a detrimental 
immune response to this protein, as well as other inflammatory signals in Parkinson’s and 
related α-synucleinopathies. In this review, the potential role of TLRs in contributing to the 
progression of these disorders is discussed. Existing evidence comes predominantly from 




and pre-clinical studies of TLR inhibitors. This evidence is evaluated in detail, and the potential 




Toll-like receptors (TLRs) are a family of transmembrane pattern recognition receptor 
(PRR) proteins key to the activation of the innate immune response. Their primary role is in 
the detection of foreign microbial and viral molecules which they achieve through their 
recognition of pathogen-associated molecular patterns (PAMPs). TLRs can also recognize 
damage-associated molecular patterns (DAMPs) which are found on molecules endogenous to 
the host (Reviewed by Bianchi, 2007). On their recognition of either PAMPs or DAMPs, TLRs 
induce a signalling cascade resulting in the activation of an immune response to clear the 
pathogen from the host or to resolve the damage. TLRs are involved in the activation of both 
the innate immune system, consisting of non-specific responses such as initiation of pro-
inflammatory cytokine production and phagocytosis, and the adaptive immune system 
consisting of a response specific to the pathogen mediated by T and B lymphocytes (Hoebe 
and Beutler, 2004). 
Microglia, the resident innate immune cells of the CNS, express all human TLRs and 
can be activated by them, eliciting inflammatory responses (Bsibsi et al., 2002). This 
involvement of TLRs in the initiation of inflammation and microglial activation in the brain 
suggests that they may play a pivotal role in neuronal dysfunction and death. In fact, several 
recent studies have implicated TLRs in neurodegenerative diseases such as Alzheimer’s 
disease, multiple sclerosis and Parkinson’s disease (PD) (Miranda-Hernandez and Baxter, 
2013; Su et al., 2016). In PD, a key theory is that the pathological protein α-synuclein activates 




exacerbates neuronal dysfunction and loss. Thus, TLRs may be an attractive therapeutic target 
for disease modification. In this review, we will discuss the evidence for a crucial role of Toll-
like receptors in α-synuclein-mediated inflammation, how this affects α-synucleinopathy 
progression in various model systems and the emerging therapeutic strategies to modulate the 
activity of these receptors. 
 
Function and localisation of TLRs 
  
The TLR family is made up of 10 functional receptors in humans (TLR1-10), and 12 in 
mice (TLR1-13; murine TLR10 is a non-functional pseudogene due to gene insertions) (Akira 
et al., 2006; Hasan et al., 2005). Each of these receptors has the ability to recognise distinct 
molecular patterns, and so allowing an appropriate immune response to be initiated. TLRs are 
type I transmembrane proteins formed of an extracellular leucine-rich repeat (LRR) domain 
responsible for specific pattern recognition, a transmembrane region, and a cytoplasmic TIR 
(Toll/interleukin-1 receptor) domain which transduces the signal to activate the correct 
downstream signalling pathway (Reviewed by Kawai and Akira, 2011). The human TLR 
family can be split into two groups based on where the receptors are located in the cell: TLR1, 
TLR2, TLR4, TLR5, TLR6, and TLR10 are found on the plasma membrane, while TLR3, 
TLR7, TLR8, and TLR9 are located in intracellular compartments (Figure 1). This differential 
localisation occurs due to the specialisation of the different members of the TLR family to 
recognise specific pathogens. The TLRs on the cell surface membrane recognise components 
of the outer membrane of microbes, such as lipopolysaccharides which are found in the 
membrane of Gram-negative bacteria and are recognised by TLR4 (Poltorak et al., 1998). The 
intracellular TLRs primarily recognise foreign nucleic acids. These TLRs are mainly expressed 




2005). This endolysosomal localisation allows for the discrimination between self and nonself 
molecules, such as viral single-stranded RNA (ssRNA) recognised by TLR7 & TLR8 (Heil et 
al., 2004), due to self nucleic acids not being present in such compartments under normal 
physiological conditions (Reviewed by Brencicova and Diebold, 2013). Similarly, TLR3 
recognises and is activated by double-stranded RNA (dsRNA) which is mainly encountered in 
viruses (Alexopoulou et al., 2001), while TLR9 cascades are triggered by unmethylated 
cytosine/guanine (CpG)-rich DNA strands which are common in bacteria but less frequent in 
mammalian cells (Hemmi et al., 2000). 
TLRs normally function in homodimers, with the exception of TLR2 which forms 
heterodimers with either TLR1 or TLR6, as well as homodimers (Jin et al., 2007; Kang et al., 
2009). Some TLRs work in combination with additional molecules or co-receptors that enable 
more sensitive ligand recognition, notably TLR4 requires both MD2 (Shimazu et al., 1999) and 
CD14 (Wright et al., 1990) to recognize and be activated by bacterial lipopolysaccharides 
(LPS). 
On PAMP or DAMP recognition by the LRR domain, the signal is transduced 
intracellularly, and the correct adapter proteins (each with a TIR domain) are recruited to and 
activated by the cytoplasmic TIR domain of the TLR to trigger the correct immune response 
(Akira et al., 2006). There are multiple adapter proteins which can be activated on pattern 
recognition by the TLR, and the combination of these proteins determines the specific 
downstream pathway. MyD88 (myeloid differentiation 88) is one such adapter protein. It can 
be activated by all TLRs with the exception of TLR3, and as such is known as the central 
adapter protein (Deguine and Barton, 2014). Recruitment of MyD88 triggers the downstream 
activation of mitogen-activated protein kinases (MAPKs) and the transcription factor NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), ultimately leading to the 




responsible for the production of pro-inflammatory cytokines such as TNFα, IL-1β and IL6 
(Kawai and Akira, 2011). NF-κB can also be activated in a MyD88-independent pathway 
involving the TLR3 and TLR4 adapter protein TRIF (TIR-domain-containing adapter-inducing 
interferon-β). This pathway results in the activation of the IRF (interferon regulatory factor) 
transcription factors in addition to NF-κB, which leads to the upregulation of cytokines and 
chemokines involved in the inflammatory response, including IP-10, MCP1, and RANTES 
(Yamamoto et al., 2003). Most signalling pathways resulting from TLR activation can be 
classified as either MyD88-dependent (the “canonical” pathway) or TRIF-dependent. Further 
adapter proteins include TRAM (TRIF-related adapter molecule) and TIRAP (TIR domain-
containing adapter protein). TRAM acts to recruit TRIF to TLR4, and TIRAP to recruit MyD88 
to TLR2 and TLR4 (Figure 1) (Akira et al., 2006; Fitzgerald et al., 2003; Horng et al., 2001, 
2002; Yamamoto et al., 2002). A detailed overview of the molecules and adapter proteins 
involved in the TLR signalling pathways can be found in Kawai and Akira, 2011. 
In the periphery, TLR expression is highest in tissues which are in close contact with 
the environment, namely the lungs and the gastrointestinal tract, as well as in peripheral blood 
mononuclear cells and the spleen (Zarember and Godowski, 2002). Several cell types, both 
immune and non-immune, have been found to express TLRs including dendritic cells, 
macrophages, B and T lymphocytes (both cytotoxic and helper T lymphocytes, although 
expression is lower in the latter), natural killer (NK) cells, as well as epithelial, endothelial and 
fibroblast cells (Yao et al., 2015; McClure and Massari, 2014; Fitzner et al., 2008; Muzio et 
al., 2000). 
Within the central nervous system, TLRs are expressed in microglia, astrocytes, and 
neurons. Human and mouse microglia express all the members of the TLR family, and their 
expression varies depending on the stimulation state of the cell and the TLR type (Bsibsi et al., 




their activation. The most highly expressed microglial TLRs are TLR1-4, with TLR2 having 
the highest expression (Bsibsi et al., 2002). Mouse astrocytes also express TLRs but at a lower 
level than microglia and lack the expression of TLRs 7 and 8 (Carpentier et al., 2005). Human 
astrocytes express TLR1-5 and TLR9 to some extent, with TLR3 being the most highly 
expressed (Bsibsi et al., 2002; Jack et al., 2005). A healthy individual shows low TLR 
expression on astrocytes, with upregulation on activation, though at a slower rate than that seen 
in microglia (Trudler et al., 2010). Microglia and astrocytes have distinct functional responses 
on exposure to TLR ligands, such as differential pro-inflammatory cytokine induction (Jack et 
al., 2005). Mouse neurons have also been shown to express TLR2, TLR3, TLR4, TLR7 and 
TLR8 (Barajon et al., 2009; Lafon et al., 2006; Ma et al., 2006; Tang et al., 2007). Human 
neurons have been shown to express TLRs 1-10, however the expression levels show high 
variation dependent on the specific TLR (Zhou et al., 2009). In neurons, a different variant of 
MyD88 is used as an adapter protein; this neuronal variant acts independently of NF-κB 
resulting in responses involving the negative regulation of growth, development, and survival 
of the TLR-induced neurons (Kim et al., 2007a). 
The activation of microglia through TLR engagement by PAMPs results in an 
inflammatory response induced to clear pathogens, but it can also be induced by endogenous 
signals (DAMPs) such as heat shock proteins, uric acid, HMGB-1 (high mobility group box 
chromosomal protein 1), and aggregated, modified, or misfolded proteins (Beraud et al., 2011; 
Bianchi, 2007). The function of the inflammatory response in the brain is to protect and restore 
neurons and glia within the CNS, particularly neurons as these cells lack the ability to 
regenerate (Ransohoff, 2016). However, in addition to neuroprotective functions such as the 
phagocytosis and subsequent destruction of misfolded proteins, neuroinflammation can also be 
detrimental.  Chronic neuroinflammation has been shown to occur in many neurodegenerative 




lateral sclerosis (ALS), and may accelerate disease development and progression through 
increased levels of proinflammatory cytokines, as well as increased oxidative and nitrosative 
stress, which all contribute to neuronal death (Frank-Cannon et al., 2009). This forms a self-
perpetuating cycle of degeneration whereby neuronal death causes immune activation, 
resulting in increased production of pro-inflammatory cytokines, chemokines and increased 
oxidative stress, which in turn leads to further neuron loss (Gao and Hong, 2008).   
 
Toll-like receptors in Parkinson’s disease 
 
PD is the second most common neurodegenerative disease after Alzheimer’s disease. 
It is characterised by the loss of dopaminergic neurons within the substantia nigra and the 
presence of α-synuclein aggregates (Lewy bodies) within the brain. Activated microglia were 
first observed in the substantia nigra of patients with Parkinson’s disease at postmortem by 
McGeer and colleagues in 1988 (McGeer et al., 1988). Subsequent studies reported an increase 
in the levels of proinflammatory cytokines in the striatum of PD brains compared to healthy 
controls, including TNFα, IL-1β, and IL-6, as well as other proteins related to microglial 
activation like cyclooxygenase and iNOS (inducible nitric oxide synthase) (Knott et al., 2000; 
Mogi et al., 1994a, 1994b). Complement activation and T lymphocyte infiltration in the 
substantia nigra of Parkinson’s postmortem brains have also been observed (Brochard et al., 
2008; Loeffler et al., 2006). In agreement with these postmortem studies, positron emission 
tomography (PET) neuroimaging using the tracer [11C]-PK11195 has demonstrated increased 
microglial activation in the brains of PD patients compared to age-matched healthy individuals, 
and this appears to start early on in the disease course (Gerhard et al., 2006; Ouchi et al., 2005). 
Microglial activation in α-synucleinopathies is thought to be triggered by α-synuclein 




disease where patients carry a mutation in the α-synuclein gene, SNCA (Polymeropoulos et al., 
1997). Following on from this, misfolded fibrillar α-synuclein was shown to be the main 
component of Lewy bodies and Lewy neurites in both PD and dementia with Lewy bodies 
(DLB) brains; Lewy bodies and neurites are the defining pathological feature of PD and DLB 
(Spillantini et al., 1997). Further research (Zhang, 2005), showed that aggregated α-synuclein 
oligomers induced microglial activation in vitro, in a primary neuron-glia co-culture system 
and that this led to increased dopaminergic neurotoxicity. Su et al. (2008) also found evidence 
for this in a PD model where mice over-expressing wild-type (WT) α-synuclein show early 
microglial activation, and in primary microglial cultures where dose-dependent α-synuclein-
mediated activation was observed. The mechanism by which aggregated α-synuclein activates 
microglia is still being established, but a key theory involves α-synuclein working as a DAMP 
and activating Toll-like receptors (Beraud et al., 2011). Initial experiments using the BV2 
microglial cell line demonstrated that treatment with α-synuclein led to altered expression of 
several TLRs, including upregulation of TLR1, TLR2, TLR3, and the adapter MyD88, and an 
increase in expression and release of pro-inflammatory molecules (Beraud et al., 2011). It has 
also been reported that the priming of cells with α-synuclein results in differential responses of 
microglia to TLR ligands, including increased secretion of pro-inflammatory cytokines 
(Roodveldt et al., 2013). In transgenic animal models, such as Thy1-α-synuclein mice which 
overexpress wild-type human α-synuclein, there is an increase in TLR1, TLR2, TLR4, and 
TLR8 mRNA expression in brain regions showing microglial activation (Watson et al., 2012). 
This upregulation of TLRs is widely seen across a number of different PD models, but the level 
and time-course of upregulation depend on the specific model (McCabe et al., 2017). It is worth 
noting that TLRs, and particularly TLR2, TLR4 and TLR9 have also been shown to be 
activated in PD models which do not show α-synuclein pathology, such as the MPTP model 




in this and similar toxin models may be induced by DAMPs related to oxidative stress, such as 
cell debris or molecules released by damaged or dying neurons including heat-shock proteins, 
the nuclear protein HMGB1 (High mobility group box 1), uric acid and others (Bianchi, 2007). 
Of particular note, TLR2 and TLR4 have been consistently reported to be upregulated 
in many α-synuclein-overexpressing or toxin-induced animal models (Drouin-Ouellet et al., 
2015; Kim et al., 2013; Noelker et al., 2013; Watson et al., 2012), and accumulating evidence 
from human studies further implicates these receptors in the pathogenesis of PD,. The majority 
of studies investigating the roles of TLRs in PD pathogenesis have focused on TLRs 2 and 4, 
with a small proportion also looking at TLR9. Though it is possible that further TLRs are 
involved in PD or other α-synucleinopathies, there is as yet no evidence to support this and as 
such, this review will specifically focus on TLR2, TLR4 and TLR9. The putative role of these 
receptors in PD is summarized in Figure 2. 
 
Toll-like receptor 2 
 
In human PD, upregulation of TLR2 has been observed in postmortem brains (Table 
1). Specifically, transcriptomic analysis revealed increased TLR2 expression in the substantia 
nigra, accompanied by an increase in the expression of genes involved in the TLR2 signalling 
pathway including CD14, IRAK2 and NF-κB (Kim et al., 2013). An increase in TLR2 protein 
levels was also observed in the caudate/putamen of postmortem PD brains (Drouin-Ouellet et 
al., 2015). Furthermore, TLR2 was found to co-localise with amoeboid microglia, suggesting 
upregulation of TLR2 expression by activated microglia in PD brains (Doorn et al., 2014; Kim 
et al., 2013; Ping et al., 2018). TLR2 has also been reported to be expressed on neurons in 
human PD brains, and the level of neuronal TLR2 expression was strongly correlated with 




available transcriptomic data from the cortex of control postmortem brains has indicated that 
TLR2 is almost exclusively expressed on microglia (Hughes et al., 2018), hence neuronal 
TLR2 expression may be disease-specific. TLR2 upregulation, as well as NF-κB activation, 
have also been identified in peripheral immune blood cells of PD patients (Ping et al., 2018; 
Drouin-Ouellet et al., 2015).  
There is also a growing body of evidence from in vitro and in vivo studies in animal 
models implicating TLR2 in the pathogenesis and progression of PD (summarized in Table 2). 
Endogenous α-synuclein binds to TLR2 to trigger microglial activation, and it has been 
suggested that this occurs in a conformation-dependent manner, with the oligomeric, but not 
monomeric or dimeric forms, acting as a TLR2 agonist (Kim et al., 2013). This was further 
verified with the use of microglia from TLR2-deficient mice, where Kim et al. (2013) showed 
diminished microglial activation indicated by a complete loss of cytokine and chemokine 
upregulation on treatment with endogenous α-synuclein released by human α-synuclein 
overexpressing SHSY5Y cells, compared to wild-type microglia. The same group later 
demonstrated that endogenous α-synuclein released from neurons induced TLR2-mediated 
microglial activation and this appeared to be neurotoxic. This neurotoxicity was entirely 
abolished by TLR2 gene depletion (Kim et al., 2016). Daniele et al. (2015) similarly showed 
that the oligomeric form of α-synuclein activates microglia, and additionally reported that this 
is mediated through a TLR1/2 heterodimer, resulting in the nuclear translocation of the p65 
NF-κB subunit. However, work by others has contradicted that it is only the oligomeric form 
of α-synuclein which can activate TLRs. Gustot et al. (2015) reported that α-synuclein fibrils, 
not oligomers or monomers, cause the activation of the NF-κB pathway through TLR2 
activation in vitro. Another study in primary human monocytes suggested that both monomeric 
and fibrillar α-synuclein instigated a TLR2-mediated inflammatory response, though α-




discrepancy results partly from a lack of consistency in the definition and size of oligomers and 
fibrils across different studies. Although the precise aggregate size which is most 
pathologically relevant in this context remains uncertain, it seems clear that at least one, if not 
several species of the protein, can act as DAMPs (Roberts and Brown, 2015). Studies in models 
of other diseases have similarly suggested that other misfolded proteins can also act as 
DAMPS, for instance, Liu et al. (2012) identified TLR2 as the receptor to which amyloid-β 
binds and initiates microglial inflammatory responses. 
Activation of neuronal TLR2 has been suggested to result in increased intracellular α-
synuclein protein. This was seen in studies by Dzamko et al. (2017) on the SHSY5Y cell line 
and IPSC-derived human neural progenitor cells using the TLR2 agonist PAM3CSK4. It is 
interesting to note that in this study there was no increase in α-synuclein expression, which 
alongside the marked increase in the expression of the autophagy marker p62 suggests 
impairment in the autophagy/lysosome degradation pathway (Dzamko et al., 2017). The TLR4 
agonist LPS did not show this effect on intracellular α-synuclein. Building on their earlier work, 
Kim et al. (2015) proposed that TLR2 activation can lead to an AKT/mTOR-mediated 
inhibition of autophagy  resulting in accumulation of α-synuclein within neurons. In this study, 
TLR2-/- mice had reduced neuronal α-synuclein accumulation, reduced microgliosis and 
astrogliosis, and showed improved motor behavioural deficits compared to control mice (Kim 
et al., 2015). 
TLR2 has also been implicated in the MPTP toxin model of PD, as shown by its 
upregulation on MPTP treatment, and subsequent upregulation of proinflammatory cytokines 
(Chao et al., 2016; Drouin-Ouellet et al., 2011; Jang et al., 2017; Koo et al., 2017). In α-
synuclein-overexpressing mice, immunization with anti-TLR2 antibodies resulted in reduced 
α-synuclein accumulation, reduced microgliosis and proinflammatory cytokine secretion, and 




2018). Furthermore, the use of a TLR2 neutralizing antibody in an in vitro set of experiments 
revealed additional roles for TLR2 in the neuron-to-neuron and neuron-to-astrocyte transfer of 
α-synuclein. Specifically, after TLR2 inhibition the neuron to neuron transfer of α-synuclein 
was markedly reduced. A similar reduction in α-synuclein transfer was observed in a co-culture 
of SHSY5Y neurons with primary human astrocytes (Kim et al., 2018).   
 
Toll-like receptor 4 
 
In human studies, analysis of transcriptomic data from postmortem control brains 
revealed ubiquitous expression of TLR4 and the adapter MyD88 throughout the brain, with 
their expression being higher in the substantia nigra and the putamen (Hughes et al., 2018) 
(Table 1). Additional studies comparing PD with control brains showed increased TLR4 
protein levels in PD cases, specifically in the substantia nigra (Shin et al., 2015) and the 
caudate/putamen (Drouin-Ouellet et al., 2015). This increase was also observed in peripheral 
immune cells in PD patients (Ping et al., 2018; Drouin-Ouellet et al., 2015; Shin et al., 2015). 
Additional evidence supporting a role of TLR4 in human PD is provided from genetic studies 
and the discovery that a polymorphism in the TLR4 gene is linked with the risk of PD in a 
Chinese Han population (Zhao et al., 2015). 
TLR4 has also been implicated through in vitro and in vivo work in animal models of 
PD, though some studies support a neuroprotective role while others argue that it acts in a 
detrimental manner (summarized in Table 3).  
Stefanova et al. (2011) showed that TLR4 ablation leads to impaired microglial 
phagocytosis of α-synuclein in an in vitro model using BV2 microglia. In the same study, TLR4 
deficiency was found to increase the dopaminergic neuron loss in the SN of an α-synuclein 




model. This neuronal death was proposed to occur due to the lack of clearing of α-synuclein 
by microglial phagocytosis, implicating TLR4 in this process (Stefanova et al., 2011). Further 
implicating TLR4 in neuroprotection, work by Mariucci et al. (2018) demonstrated that 
overexpression of α-synuclein mRNA occurs in TLR4-/- mice in several brain areas, though the 
causes of this have not been elucidated.  
Conversely, TLR4 has been implicated in the MPTP toxin model of PD, with MPTP 
treatment resulting in TLR4 upregulation, and inhibition of TLR4, either by gene knockout or 
with siRNA silencing, ameliorating MPTP induced deficits. For instance, TLR4-/- mice 
appeared to be less vulnerable to the toxin as they showed less dopaminergic cell death, in 
addition to fewer activated nigral microglia (Mariucci et al., 2018; Conte et al., 2017; Zhao et 
al., 2016; Noelker et al., 2013). Recently, Campolo et al. (2018) added to this data by showing 
that the absence of TLR4 also leads to inhibition of inflammasome activation and an 
improvement in MPTP-induced motor impairments. Zhou et al. (2016) using an in vitro TLR4 
siRNA silencing approach found a reduction in microglial activation after MPTP treatment and 
decreased NF-κB activation. Upregulation of TLR4 was observed in an additional toxin model 
induced by 6-hydroxydopamine (6-OHDA); in this model TLR3 expression was also 
upregulated (McCabe et al., 2017). In a rotenone-induced model, motor deficits and 
dopaminergic cell loss were ameliorated in TLR4-/- animals (Perez-Pardo et al., 2018). 
Recent work suggests that not only TLR2 but also TLR4 is necessary for the recognition 
of α-synuclein and initiation of inflammatory responses. Upon α-synuclein stimulation, TLR4-
deficient microglia produced significantly less TNFα and reactive oxygen species, compared 
to wild-type microglia (Fellner et al., 2013). In agreement with this, Shao et al. (2018) recently 
showed that either pharmacological inhibition or gene depletion of TLR4 in microglia in vitro 
attenuates α-synuclein-induced TNFα secretion. Further work showed TLR4 to be involved in 




proinflammatory cytokines through activation of the NF-κB pathway (Rannikko et al., 2015). 
This data suggests that TLR4 is responsible for detecting α-synuclein as a DAMP and initiating 
an immune response. Work by Hughes et al., 2018 revealed that physiological levels of soluble 
oligomeric α-synuclein (but not monomers or fibrils) could induce TLR4-mediated cytokine 
production in microglia in vitro, with a 10- to 100-fold reduction in TNF production induced 
by α-synuclein in TLR4-/- microglia compared to wild-type. The reduction in the inflammatory 
response to α-synuclein in TLR2-/- microglia compared to wild type was much more modest, 
thus suggesting that the TLR4 pathway is the primary mechanism underlying the microglial 
response to oligomeric α-synuclein at physiological concentrations.  
Finally, recent evidence implicates TLR4 activation in the gastrointestinal tract with 
PD pathogenesis. It has been widely proposed that α-synuclein pathology in PD may be 
initiated in the periphery, specifically in the intestinal and/or olfactory mucosa (Hawkes et al., 
2007), and α-synuclein aggregates are present in human colonic mucosa even in very early 
disease (Malek et al., 2014). In further support of early gut involvement in PD, patients have 
been found to have an altered microbiome in the intestine (Keshavarzian et al., 2015; 
Scheperjans et al., 2015). Furthermore, studies in germ-free α-synuclein-overexpressing mice 
have demonstrated that colonisation of the gut with microbiota from PD patients exacerbates 
disease severity, compared with colonisation with microbiota from healthy human donors 
(Sampson et al., 2016). As such, the microbiome itself may play a role in driving disease 
progression by triggering an abnormal inflammatory response. TLR4 is primarily activated by 
lipopolysaccharides found on the surface of Gram-negative bacteria (Poltorak et al., 1998) and 
is therefore uniquely poised to sense and be activated by dysbiotic gut microbiota. In line with 
this theory, Perez-Pardo et al. (2018) have demonstrated increased expression of TLR4 mRNA 
in human intestinal mucosal biopsy samples  from PD patients compared to controls, with a 




chemokines (CCL2, CCL5) in the sigmoid mucosa. In a second set of experiments using the 
rotenone mouse model of PD, the same authors showed that TLR4-/- mice were protected to 
some extent from the toxic effects of rotenone both in the gut and the brain, and their motor 
deficit was significantly less severe compared to wild-type rotenone-treated mice. However, in 
a different study it was found that the knockout of MyD88 had no effect on the MPTP 
treatment-induced degeneration of the dopaminergic nigrostriatal pathway (Drouin-Ouellet et 
al., 2011) despite the increased survival of myenteric dopaminergic neurons seen in the same 
MPTP-treated MyD88-/- mice (Côté et al., 2011). In another animal study, transplantation of 
faecal microbiota from wild-type to MPTP mice led to reduced activation of the TLR4 
pathway, dopaminergic neuron rescue and improved motor function (Sun et al., 2018).  
In summary, there is evidence to suggest that TLR4 may have both neuroprotective and 
detrimental roles in PD, although this may depend on the model system, or on the timepoint in 
the disease process. Specifically, in an acute setting or in early disease, TLR4 activation by α-
synuclein may promote microglial phagocytosis to facilitate intracellular degradation of 
aggregated α-synuclein. Conversely in the setting of chronic inflammation, in either the gut or 
brain, TLR4 may play a critical role in escalating the inflammatory response (Fellner et al., 
2013; Lee et al., 2008).  
 
Toll-like receptor 9 
 
Evidence is emerging that there may also be a role for TLR9 in PD (Table 1). TLR9 
was found to be upregulated in human striatal homogenates from PD patients, mirroring an 
MPTP-induced upregulation of TLR9 in mice (Ros-Bernal et al., 2011). Polymorphisms in the 
TLR9 gene (as well as TLR4) have also been reported to be associated with PD in a Chinese 




linked with PD susceptibility, but only in females (Zhu et al., 2016). This SNP is relatively 
common (found in 44% of Caucasians, Japanese and Chinese, and in 67% of African 
Americans), though its functional significance has not been explored yet (Cheng et al., 2007). 
The role of TLR9 in PD was recently investigated in an MPTP mouse model where TLR9 
ablation by gene knockout was found to be protective against dopaminergic cell death in the 
substantia nigra (Maatouk et al., 2018). The authors further proposed a regulatory role for 
glucocorticoid receptors (GR) in the TLR9 mediated response.  Specifically, TLR9 stimulation 
via injection of its agonist CpG ODN in control and GR knockout mice led to dopaminergic 
cell loss which was more pronounced in the GR knockout group. This data suggests that GR 
may play a protective role in TLR9-mediated neurodegeneration (Maatouk et al., 2018), which 
if replicated in further studies, would raise interesting therapeutic implications. 
 
Toll-like receptors in other synucleinopathies 
 
If α-synuclein plays a key role in the activation of Toll-like receptors 2 & 4, as the 
literature suggests, one would expect TLR activation to be a common mechanism across other 
“α-synucleinopathies” including dementia with Lewy bodies (DLB), and multiple system 
atrophy (MSA). Although studies have been more limited in these conditions, evidence of TLR 
activation has been similarly reported, as reviewed below.  
 
Dementia with Lewy Bodies 
 
DLB is a common form of dementia. Pathologically and clinically there is overlap with  
Parkinson’s disease dementia (PDD), although clinically the 2 conditions differ in terms of 




features in PDD) (McKeith et al., 2005), and recent evidence suggests that they have distinct 
genetic associations at the SNCA locus (Guella et al., 2016). However, the cortical α-synuclein 
aggregates (Lewy bodies) formed in DLB cannot be distinguished from those seen in PD 
dementia.  
Similar to work previously discussed in human postmortem PD brains, increased 
numbers of activated microglia have been found in the trans-entorhinal cortex of DLB brains 
(Mackenzie, 2000), and subsequent PET neuroimaging studies using the TSPO ligand 
PK11195 have confirmed microglial activation in subcortical and cortical regions in early stage 
DLB (Iannaccone et al., 2013). In conjunction with this, TLR2 protein levels are increased in 
DLB post mortem brain. Specifically, western blotting in temporal cortex homogenates showed 
a significant increase in TLR2, while immunohistochemical analysis revealed increased co-
localization of TLR2 with microglia but not neurons, as compared to control brains (Kim et al., 
2013). Garcia-Esparcia et al. (2017) found no change in the mRNA expression level of TLR4 
and TLR7 in postmortem frontal cortices of cases with DLB, or rapid DLB (2 years from 
symptom onset to death) compared to neurologically intact controls but did not evaluate TLR2.  
 
Multiple system atrophy 
 
Multiple system atrophy is an α-synucleinopathy which is more distinct in its pathology 
and clinical phenotype than DLB and PD. It is characterised by early autonomic disturbance as 
well as parkinsonism and cerebellar features, and a more rapidly progressive course than PD 
with minimal response to levodopa.  Pathologically, the α-synuclein aggregates in MSA differ 
from Lewy bodies both in their glial location and their solubility – these aggregates are known 




As in other α-synucleinopathies, human MSA postmortem brains exhibit increased 
region-specific microglial activation correlating with α-synuclein glial cytoplasmic inclusions 
as well as neuronal loss compared to controls (Stefanova et al., 2007; Ishizawa et al., 2004), 
with similar findings in an animal model of the disease (Stefanova et al., 2007). TLR4 
expression was found to be increased both in an animal model of MSA and in human 
postmortem MSA brain (Stefanova et al., 2007). Other TLRs have also been reported to be 
upregulated in MSA in a brain region-specific manner: TLR3, TLR4, and TLR5 in the SN, 
striatum, cerebral cortex, and nucleus dentatus; TLR1 in the SN and striatum only, and TLR8 
and TLR9 in the cerebellum (Brudek et al., 2013). Interestingly TLR4 expression was also 
increased in the colonic sigmoid mucosa of MSA patients raising the possibility that 
neuroinflammation in MSA may be sustained or driven by inflammation in the gut, as has also 
been suggested in PD (Engen et al., 2017). A change in TLR2 expression in MSA has not been 
reported. This raises the possibility that TLRs may play distinct roles according to the nature 
of the α-synuclein aggregates (GCIs versus Lewy bodies). 
The potential neuroprotective role of TLR4 in MSA has also been investigated using 
the TLR4 agonist monophosphoryl lipid A (MPLA), a chemically detoxified form of the 
common TLR4 agonist lipopolysaccharide (LPS), which does not instigate neuroinflammatory 
responses (Venezia et al., 2017). Upon MPLA injection in the brain of α-synuclein-
overexpressing mice, increased α-synuclein clearance, reduced nigral dopaminergic neuron 
death, and a region-specific decrease in intracellular α-synuclein aggregates was seen. The 
beneficial role of TLR4 stimulation seen in this work indicates that MPLA may warrant further 
consideration as a potential therapeutic compound (Venezia et al., 2017). Interestingly, in this 
same study, chronic TLR4 stimulation by LPS resulted in decreased monomeric α-synuclein, 




Hence TLR4 may have dual roles to play in both neuroinflammation and α-synuclein aggregate 
clearance in MSA.  
 
Potential therapeutic strategies 
 
There is an increasing interest in the possible use of therapeutics aimed at preventing 
or stopping neuroinflammation in PD and other α-synucleinopathies. Dying or injured neurons 
can release noxious molecules in the extracellular milieu such as misfolded or aggregated 
proteins (e.g., α-synuclein), cytosolic compounds like neuromelanin, or other altered molecules 
(e.g. the matrix metalloproteinase-3) (Kim et al., 2007b; Zhang, 2005; Zecca et al., 2003). 
These self-molecules can serve as stimuli (DAMPs) to initiate an inflammatory response. This 
initial acute response can be beneficial for the injured tissue by promoting clearance of cell 
debris and by releasing neurotrophic factors to enhance neuronal survival (Gao and Hong, 
2008; Trapp et al., 2007; Kordower, 2003). However, an uncontrolled chronic 
neuroinflammatory response will result in the prolonged secretion of pro-inflammatory 
cytokines, reactive oxygen species and nitric oxide, which are neurotoxic and will exacerbate 
neuronal injury and death (Gao and Hong, 2008). Therefore, the immune system’s capacity to 
play a role in propagating neuronal dysfunction within the brain could contribute to the 
progressive nature of PD. 
Most proposed immune-modulating therapies to date are rather non-specific in their 
targeting of the immune/inflammatory response, thus leading to a broad range of adverse 
effects (Wang et al., 2015). TLRs provide a specific route for therapeutic development. Several 
TLR compounds have been explored - mostly in animal models of PD - but these agents vary 




approaches explored thus far include the use of small molecule inhibitors, repurposed pre-
existing drugs, and natural compounds. 
Small synthetic molecules, including TLR signalling inhibitors, have recently been 
explored for their therapeutic capacity in neurodegenerative diseases. TAK242, or resatorvid, 
is one such small molecule, which specifically suppresses the activation of TLR4 by interacting 
with the receptor’s intracellular TIR domain (Ii et al., 2006; Kawamoto et al., 2008). TAK242 
has been used in amyotrophic lateral sclerosis (ALS) and traumatic brain injury (TBI) animal 
models showing, in both cases, neuroprotective effects and behavioural improvement by 
blocking TLR4 signalling and thereby reducing neuroinflammation (Fellner et al., 2017; Feng 
et al., 2017). As previously discussed, oligomeric α-synuclein is hypothesized to exert at least 
some of its inflammatory effects by binding to TLR4. Hughes et al. (2018) tested whether 
TAK242 or RSLA (another small molecule inhibitor of TLR4) could inhibit the neurotoxic 
effects of physiological α-synuclein levels in vitro. Pre-treatment with either of these inhibitors 
significantly reduced α-synuclein-induced oxidative stress and cell death in neuronal cultures. 
Furthermore, the same authors showed that TNFα production by microglia in culture upon α-
synuclein treatment was also significantly attenuated by TAK242 or RSLA treatment. TAK242 
has previously been used in a Phase I randomized, double-blind, placebo-controlled clinical 
trial for the treatment of sepsis, which although negative for its primary outcome, demonstrated 
the safety and tolerability of this compound, at least for short term use (4 days) (Rice et al., 
2010). Although these studies were on disorders other that α-synucleinopathies, they indicate 
that TAK242 could have beneficial effects in PD through the blocking of TLR4 and subsequent 
decrease in the neuroinflammatory effects of α-synuclein. CU-CPT22 is another small 
molecule inhibitor which is selective for TLR1/2. This molecule led to a reduction of NF-κB 
nuclear translocation with a concomitant decrease in TNFα production in primary microglia 




In the field of neurodegenerative disease, it is becoming increasingly common for the 
therapeutic potential of drugs already licenced for other conditions to be explored (so-called 
“drug repurposing”). One such candidate is vinpocetine which is used clinically in the 
treatment of cerebrovascular diseases due to its neuroprotective action and its effects on 
cerebral blood flow (Zhang and Yang, 2014; Patyar et al., 2011; Szilágyi et al., 2005). In vitro 
studies have revealed anti-inflammatory properties of vinpocetine through the inhibition of NF-
κB activation (Dastidar et al., 2007; Fan Chung, 2006; Banner and Trevethick, 2004). In a 
recent double-blind placebo-controlled trial, PD patients were randomised to treatment with 
vinpocetine or placebo alongside standard levodopa therapy for 14 days, and TLR2, TLR3, and 
TLR4 mRNA expression levels in peripheral blood monocytes were measured before and after 
treatment (Ping et al., 2018). The vinpocetine-treated group showed a reduction in TLR2 and 
TLR4 expression and an increase in TLR3 expression compared to the placebo group, as well 
as downregulation of MyD88, NF-κB, and TNFα, and a greater improvement in patient 
cognitive function. It is uncertain whether the improved cognitive function observed here was 
due to anti-inflammatory or other vinpocetine-induced mechanisms, however, it is an attractive 
candidate for further study (Ping et al., 2018). Another potential candidate of interest is 
Candesartan cilexetil, a licensed drug for treating hypertension (angiotensin II receptor 
blocker), which has recently been shown to suppress TLR expression (specifically TLR2 and 
TLR4). Dasu et al. (2009) demonstrated that Candesartan treatment reduced the expression of 
both TLR2 and TLR4, inhibited the secretion of pro-inflammatory mediators such as TNFα, 
IL-1β and IL6, and was protective against LPS challenge, both in vitro in primary human 
monocytes and in vivo in mice. Furthermore, Candesartan has been shown to produce dose-
dependent rescue of microglial phenotype and function after α-synuclein stimulation in vitro 
(Daniele et al., 2015). Finally, Candesartan was shown to be neuroprotective and exerted anti-




Telmisartan (another angiotensin II receptor blocker), or vehicle for two weeks were then 
injected with an AAV9 virus expressing α-synuclein. Vehicle-treated α-synuclein animals 
showed pronounced dopaminergic cell loss in the substantia nigra, increased microglial 
activation and secretion of pro-inflammatory mediators and showed a significant motor deficit. 
All these effects were to an extent reversed in both the Candesartan- and the Telmisartan-
treated group, though the effect of these two drugs on TLRs was not interrogated (Rodriguez-
Perez et al., 2018). Nevertheless, this work suggests that Candesartan may warrant further 
consideration as a candidate for drug repurposing for PD.  
Naturally-derived compounds have also been investigated regarding their use in 
treating neurodegenerative diseases due to having multiple pharmacological properties. One 
such naturally-derived compound is Curcumin, an Indian herb extracted from Curcuma longa 
root which has been demonstrated to have anti-inflammatory and anti-oxidative effects in vitro 
and in vivo (Monroy et al., 2013). It has been shown to act directly on the TLR4 pathway in 
vitro by inhibiting  TLR4 receptor dimerisation and resulting in repression of the TLR4 
pathway (Youn et al., 2006). Yu et al. (2016) investigated its effects in an in vitro MPTP model 
of PD and found that pre-treatment with Curcumin inhibited the MPTP-induced activation of 
primary rat astrocytes in culture, the subsequent production of pro-inflammatory cytokines, 
and the activation of TLR4 and several components of its downstream signalling pathway. 
These experiments suggest that Curcumin could work in a neuroprotective manner through the 
repression of TLR4 signalling and subsequent microglial activation and associated 
neuroinflammation. It is notable that the suitability of this compound for translation into 
clinical trials has already been demonstrated in other neurodegenerative diseases, although the 
results of these studies have been mixed. (Ringman et al., 2012; Baum et al., 2008; Small et 
al., 2018). Further work is required to demonstrate that the beneficial effects of Curcumin seen 




disease. Finally, other natural compounds including Asiatic acid, Juglanin, Vitamin D, and 
Quercetin have been demonstrated to have anti-inflammatory properties and a subset appear to 
show neuroprotective effects (Lv et al., 2018; Chao et al., 2016; Phan et al., 2010; Zhang and 
Xu, 2018; Calvello et al., 2016; Zhang et al., 2016). The downregulation of TLRs has been 
observed in many of these studies, and it has been suggested that the neuroprotective effects of 
these natural compounds occur through the  inhibition of TLRs and subsequent reduction in 
inflammation (Chao et al., 2016; Zhang and Xu, 2018; Calvello et al., 2016; Zhang et al., 2016). 
Nevertheless, further work is required to determine whether these naturally derived chemicals 
are acting directly on the TLR pathways. 
 
Conclusion and future perspectives 
 
Toll-like receptors may play a key role in α-synucleinopathies, including Parkinson’s 
disease, as shown by in vitro, animal model, and patient studies. Neuroinflammation is thought 
to be instrumental in the aetiology and progression of neurodegenerative diseases, and the 
activation of TLRs by aggregated α-synuclein provides a mechanism by which this 
neuroinflammation may occur. TLR2 and TLR4 appear to be the most relevant TLRs in α-
synucleinopathies and are suggested to be responsible for the detection of aggregated forms of 
α-synuclein. There remains some dispute in the field over which of these is most critical in 
mediating neuroinflammation in α-synucleinopathies. Seemingly contrasting data in the 
literature may reflect differences in model systems used, or in the preparation of α-synuclein 
aggregates. However, both TLR2 and 4 may contribute in a complimentary way. Recent 
evidence proposes that TLR4 activation in the periphery may be critical, especially in the 
gastrointestinal tract, where it may be involved in detecting gut dysbiosis, whilst the role of 




synucleinopathies. A number of pre-clinical studies have tested TLR-binding compounds in 
animal models and demonstrated that these agents could alleviate features of α-
synucleinopathies, specifically inflammation, and through this improve behavioural 
phenotype. Many of these compounds are suitable for clinical trials, but it remains to be seen 
whether their effects are translatable to human PD. Nevertheless, targeting Toll-like receptors 
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Figure 1 Legend 
 
Figure 1: Cellular localisation and signal transduction of human Toll-like receptors 
(TLRs). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 are located on the plasma membrane 
while TLR3, TLR7, TLR8 and TLR9 are found intracellularly on endosomal or lysosomal 
membranes. Most TLRs are believed to function in homodimers, though TLR2 forms 
heterodimers with either TLR1 or TLR6. All TLRs except for TLR3 signal through a MyD88 
(myeloid differentiation 88)- dependent downstream pathway. Signalling via TLR2 and TLR4 
requires an additional intracellular adapter protein TIRAP (TIR domain-containing adapter 
protein), which in turn recruits the central adapter MyD88. This triggers a downstream 
signalling cascade resulting in the nuclear translocation of the transcription factor NF-κB and 
the expression of pro-inflammatory cytokines such as TNFα, IL-1β and IL6. There is also a 
MyD88-independent pathway which involves TLR3 and TLR4. Activation of TLR3 engages 
the adapter protein TRIF (TIR-domain-containing adapter-inducing interferon-β), while TLR4 
signalling requires both TRAM (TRIF-related adapter molecule) and TRIF. This results in the 
downstream activation of the IRF transcription factors (interferon-regulatory factor) which 
regulate the expression of interferon type 1 genes. Abbreviations: ssRNA: single-stranded 













Figure 2 Legend 
 
Figure 2: The putative role of TLR2, TLR4 and TLR9 in the PD brain. 
Oligomeric α-synuclein or other DAMPs activate neuronal TLR2 leading to downstream 
AKT/mTOR-mediated inhibition of autophagy. This results in accumulation of α-synuclein 
inside neuronal cell bodies and neurotoxicity. Neuron-released α-synuclein or other DAMPs 
can activate microglia via TLR2 and TLR4 triggering a signalling cascade that results in the 
translocation of the transcription factors NF-κB and IRF to the nucleus thereby initiating the 
production and secretion of pro-inflammatory cytokines and chemokines. These can exacerbate 
neuronal damage and may also recruit peripheral immune cells to the CNS. Activation of NF-
κB could also be triggered by TLR9, though its role in PD is less clear. Microglial TLR4 may 
play an additional role in promoting the phagocytic clearance of misfolded  α-synuclein. Finally, 
neuron-released α-synuclein may also trigger astrocyte activation via TLR2 and/or TLR4, 
inducing the production of pro-inflammatory mediators which can further contribute to 
microglial activation. Abbreviations: TLR: Toll-like receptor; DAMPs: damage-associated 
molecular patterns; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; 









Table 1. Summary of studies evaluating TLRs in PD patients. 
References Study design Key observation 
Dzamko et al., 2017; 
Drouin-Ouellet et al., 2015 
Human PD and control postmortem brains   
TLR2 level is increased in the striatum and anterior cingulate cortex 
of PD brains. 
Ping et al., 2018; Dzamko et 
al., 2017; Doorn et al., 
2014; Kim et al., 2013 
Human PD and control postmortem brains   
Increased co-localization of TLR2 with activated microglia in PD 
brains. Neuronal TLR2 correlates with disease burden and duration. 
Hughes et al., 2018; 
Drouin-Ouellet et al., 2015; 
Shin et al., 2015 
Human PD and control postmortem brains   
TLR4 protein levels are increased in the substantia nigra and 
caudate/putamen of PD brains.  
Ros-Bernal et al., 2011 Human PD and control postmortem brains TLR9 protein level is increased in the striatum of PD brains. 
Ping et al., 2018; Drouin-
Ouellet et al., 2015; Shin et 
al., 2015 
Human PD and control PBMCs  TLR2, TLR4, and NF-κB are upregulated in PD PBMCs. 
Perez-Pardo et al., 2018 
Human PD and control intestinal mucosa 
biopsies  
TLR4 and pro-inflammatory cytokine expression is upregulated in 
the intestinal mucosa of PD patients compared to controls. 
Zhu et al., 2016; Zhao et al., 
2015 
PD and healthy Chinese Han population TLR4 and TLR9 polymorphisms are associated with PD. 









Table 2. Summary of studies evaluating TLR2 in in vitro and in vivo PD models. 
References Study design Key observation 
Beraud et al., 2011 α-Synuclein-treated BV2 microglia Upregulation of microglial TLR2. 
Kim et al., 2013 
α-Synuclein-treated WT & TLR2-/- mouse 
microglia   
TLR2-mediated microglial activation. 
Daniele et al., 2015 
Mouse microglia treated with α-synuclein 
and TLR2 antagonists  
Inhibition of TLR1/TLR2 ameliorates inflammation. 
Gustot et al., 2015 
THP1 cells treated with α-synuclein and 
anti-TLR2 antibodies 
Fibrillar α-synuclein activates TLR2.  
Codolo et al., 2013 
Human monocytes treated with anti-TLR2 
antibodies prior to α-synuclein 
Both fibrillar and monomeric α-synuclein activate TLR2. 
Dzamko et al., 2017 
SHSY5Y and IPSC-derived neural cells 
treated with a TLR2 agonist 
Neuronal TLR2 activation leads to increase α-synuclein. 
Kim et al., 2015 
SHSY5Y cells treated with TLR2 agonist 
and autophagy inducer or inhibitor 
Neuronal TLR2 regulates autophagy. 
Kim et al., 2016 WT & TLR2-/- mice TLR2-mediated microglial activation is neurotoxic. 
Kim et al., 2015 A53T+ TLR2+/+ and A53T+TLR2-/- mice 
TLR2 ablation reduces neuronal α-synuclein accumulation and 
improves motor function. 
Chao et al., 2016; Drouin-
Ouellet et al., 2011 
MPTP mice  MPTP treatment upregulates TLR2. 
Kim et al., 2018 
Anti-TLR2 immunization of α-synuclein 
overexpressing mice  
Anti-TLR2 immunization alleviates neuroinflammation, 
neurodegeneration and behavioural deficits. 
La Vitola et al., 2018 Anti-TLR2 immunization of WT mice  
Anti-TLR2 pre-treatment ameliorates α-synuclein-induced memory 
deficits. 
PD: Parkinson’s disease; WT: wild-type; SHSY5Y: human neuroblastoma cell line; BV2: mouse microglia cell line; THP1 cells: human monocyte 







Table 3. Summary of studies evaluating TLR4 in in vitro and in vivo PD models. 
References Study design Key observation 
Shao et al., 2018; Fellner et 
al., 2013 
α-Synuclein-treated WT or TLR4-/- mouse 
microglia 
α-Synuclein triggers microglial activation through TLR4. 
Rannikko et al., 2015 
α-Synuclein-treated WT or TLR4-/- mouse 
astrocytes 
α-Synuclein triggers astrocytic activation through TLR4. 
Stefanova et al., 2011 BV2 microglia with anti-TLR4 antibody  TLR4 inhibition impedes microglial α-synuclein phagocytosis. 
Zhou et al., 2016 
TLR4 knockdown in MPTP-treated BV2 
microglia  
TLR4 silencing reduces MPTP-induced microglial activation. 
Mariucci et al., 2018 WT & TLR4-/- mice α-Synuclein expression is upregulated in the brain of TLR4-/- mice. 
Stefanova et al., 2011 TLR4-/- MSA mouse model TLR4 ablation exacerbates DA neuronal loss and motor deficits. 
Mariucci et al., 2018; Conte 
et al., 2017; Zhao et al., 
2016; Noelker et al., 2013 
WT & TLR4-/- MPTP mice  
MPTP treatment upregulates TLR4. TLR4 ablation rescues MPTP-
induced neuroinflammation, neurotoxicity and motor deficits. 
Campolo et al., 2018 WT & TLR4-/- MPTP mice TLR4 ablation blocks inflammasome activation. 
McCabe et al., 2017 WT & 6-OHDA lesioned rats On 6-OHDA lesioning, striatal TLR4 expression is increased. 
Perez-Pardo et al., 2018 WT & TLR4-/- rotenone-treated mice 
TLR4 knockout partially rescues dopaminergic cell loss in the 
substantia nigra and ameliorates the motor deficits. 
PD: Parkinson’s disease; WT: wild type; BV2: mouse microglia cell line; MSA: multiple system atrophy; 6-OHDA: 6-hydroxydopamine; PBMCs: 







 Misfolded proteins like α-synuclein can act as DAMPs leading to activation of TLRs, 
a major component of the innate immune system. 
 TLRs may be a key mediator of neuroinflammatory responses in PD and other α-
synucleinopathies. 
 Targeting TLRs could be an effective therapeutic strategy for reducing 
neuroinflammation in PD and slowing down the disease progression. 
 
